hyperhomocysteinemia is an independent predictor of long-term clinical outcomes in Chinese octogenarians with acute coronary syndrome

Objective: To evaluate the prognostic value of homocysteine (Hcy) in Chinese acute coronary syndrome (ACS) octogenarians. Methods: The study cohort comprised 660 consecutive ACS octogenarians who underwent coronary angiography. We classified the patients into three groups according to Hcy tertiles. Kaplan–Meier method was performed for survival and major adverse cardiac events (MACE) rates. Multivariate Cox regression was performed to identify mortality predictors. Receiver operating characteristic curve analysis was performed to predict the cutoff value of Hcy for all-cause mortality. Results: The follow-up period was 28 (inter-quartile range: 16–38) months. Diastolic blood pressure, ratios of male, renal failure and old myocardial infarction in high plasma level Hcy (H-Hcy) group were higher than those in low (L-Hcy) and middle (M-Hcy) plasma level of Hcy groups ( P , 0.05). The Hcy level was positively correlated with uric acid level ( r = 0.211, P = 0.001) and Cystatin C (Cys C) level ( r = 0.212, P = 0.001) and negatively correlated with estimated glomerular filtration rate ( r =- 0.148, P = 0.018). For the long-term outcomes, the cumulative survival rate of H-Hcy group was significantly lower than that of L-Hcy and M-Hcy groups ( P = 0.006). All-cause mortality and MACE of H-Hcy group were higher than those of L-Hcy and M-Hcy group ( P = 0.0001, P = 0.0008). Hcy is an independent predictor for long-term all-cause mortality (odds ratio = 2.26, 95% CI = 1.23–4.16, P = 0.023) and MACE (odds ratio = 1.91, 95% CI = 1.03–3.51, P = 0.039). Receiver operating characteristic curve analysis indicated the predictive cutoff value of Hcy for all-cause mortality was 17.67 µ mol/L (0.667, 0.681). Conclusion: In ACS octogenarians, hyperhomocysteinemia is an important predictor for long-term all-cause mortality and MACE.

[1]  Xiao-ming Shang,et al.  Correlation Between Hyperhomocysteinemia and Outcomes of Patients With Acute Myocardial Infarction , 2016, American journal of therapeutics.

[2]  H. Suryapranata,et al.  Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid , 2015, Journal of cardiovascular pharmacology.

[3]  L. Sechi,et al.  Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. , 2015, American journal of hypertension.

[4]  S. Fu,et al.  Multimarker Analysis for New Biomarkers in Relation to Central Arterial Stiffness and Hemodynamics in a Chinese Community-Dwelling Population , 2015, Angiology.

[5]  A. Levi,et al.  Assessment of a Possible Link Between Hyperhomocysteinemia and Hyperuricemia , 2015, Journal of Investigative Medicine.

[6]  Silvia Lai,et al.  Early markers of cardiovascular risk in chronic kidney disease , 2015, Renal failure.

[7]  Yundai Chen,et al.  Correlation between comprehensive evaluation of coronary artery lesion severity and long-term clinical outcomes in Chinese octogenarians with acute coronary syndrome. , 2014, Heart, lung & circulation.

[8]  A. Esteghamati,et al.  Homocysteine and metabolic syndrome: from clustering to additional utility in prediction of coronary heart disease. , 2014, Journal of cardiology.

[9]  E. Akbal,et al.  Increase in the risk of ST elevation myocardial infarction is associated with homocysteine level. , 2014, Archives of medical research.

[10]  H. Suryapranata,et al.  Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. , 2014, Thrombosis research.

[11]  H. Zhang,et al.  Coronary flow velocity reserve is impaired in hypertensive patients with hyperhomocysteinemia , 2014, Journal of Human Hypertension.

[12]  A. Miled,et al.  Clinical Utility of Serum Cystatin C in Predicting Coronary Artery Disease in Patients Without Chronic Kidney Disease , 2014, Journal of clinical laboratory analysis.

[13]  Yundai Chen,et al.  Long-term prognostic impact of cystatin c on acute coronary syndrome octogenarians with diabetes mellitus , 2013, Cardiovascular Diabetology.

[14]  J. Drzewoski,et al.  Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study. , 2013, Pharmacological research.

[15]  Y. Hu,et al.  Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China , 2013, Herz.

[16]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[17]  D. Levy,et al.  Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study , 2012, Circulation.

[18]  S. Tyagi,et al.  Homocysteine and Hypertension in Diabetes: Does PPARγ Have a Regulatory Role? , 2010, PPAR research.

[19]  Saskia le Cessie,et al.  Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study , 2009, BMJ : British Medical Journal.

[20]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[21]  Fang Wang,et al.  Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[23]  Song-min Huang,et al.  Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[25]  S. Tyagi,et al.  Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation , 2004, Nutrition journal.

[26]  G A Beller,et al.  Demographics and cardiology, 1950-2050. , 2000, Journal of the American College of Cardiology.

[27]  G. Gensini,et al.  A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.

[28]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[29]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[30]  Georgia Salanti,et al.  Homocysteine lowering interventions for preventing cardiovascular events. , 2009, The Cochrane database of systematic reviews.

[31]  E. Falk,et al.  Homocysteine and atherothrombosis , 2001, Lipids.